Analytical Method Development: Analytical Target Profile (ATP) Documentation – V 2.0
SOP for Documentation of Analytical Target Profile (ATP) in Method Development
Department |
Analytical Method Development |
SOP No. |
SOP/AMD/015/2025 |
Supersedes |
SOP/AMD/015/2022 |
Page No. |
Page 1 of 14 |
Issue Date |
19/05/2025 |
Effective Date |
20/05/2025 |
Review Date |
19/05/2026 |
1. Purpose
This SOP defines the procedure for documenting the Analytical Target Profile (ATP), which serves as the foundational guideline for developing and validating analytical methods. The ATP ensures that analytical methods meet
their intended purpose with respect to accuracy, precision, specificity, and other performance attributes aligned with ICH Q8 and Q14 expectations.
2. Scope
This SOP applies to all analytical development scientists, team leads, and quality reviewers involved in method design, optimization, validation, and technology transfer in the Analytical Method Development (AMD) department.
3. Responsibilities
- Analytical Scientist: Drafts the ATP based on the intended use and product quality requirements.
- Team Lead: Reviews ATP for scientific rationale and technical completeness.
- QA Representative: Ensures ATP meets documentation requirements and regulatory alignment.
- Head – AMD: Approves ATP and ensures it is referenced in all subsequent method development documentation.
4. Accountability
The Head of AMD is accountable for ensuring that all analytical method development activities are guided by a formally approved ATP that is scientifically justified and clearly defines method performance requirements.
5. Procedure
5.1 Definition and Importance of ATP
- The ATP defines the objective of the analytical method by specifying what is to be measured and the required method performance criteria (e.g., precision, accuracy, range, detection limit).
- The ATP acts as a benchmark for method design, optimization, and validation stages.
5.2 Initiation of ATP
- Initiate ATP documentation during the early phase of product development or upon receipt of a method development request.
- Assign ATP number in the format: ATP/YY/XXX (e.g., ATP/25/015).
- Record initiation details in Annexure-1: ATP Tracker.
5.3 Structure of ATP Document
- The ATP must include the following components:
- Product/Analyte Identification
- Method Objective (e.g., quantification, identification)
- Analytical Technique (e.g., HPLC, GC, UV)
- Performance Characteristics:
- Accuracy (e.g., 98–102%)
- Precision (e.g., %RSD ≤ 2%)
- Specificity
- Range and Linearity (e.g., 80–120%)
- Detection and Quantitation Limits
- Intended Use (e.g., assay for release testing)
- Justification and Risk Assessment (if applicable)
- Use Annexure-2: ATP Template for drafting.
5.4 Review and Approval
- Submit the draft ATP to the Team Lead and QA.
- Address feedback, finalize the document, and route for approval by Head – AMD.
- Attach signed approval sheet as Annexure-3.
5.5 Implementation and Use
- Reference ATP in all associated documents:
- Method Development Protocol
- Method Development Report
- Validation Protocol and Report
- Use ATP as the basis for establishing system suitability criteria and validation acceptance limits.
- Maintain updated versions with documented justifications in case of revisions.
6. Abbreviations
- ATP: Analytical Target Profile
- AMD: Analytical Method Development
- RSD: Relative Standard Deviation
- HPLC: High-Performance Liquid Chromatography
- QA: Quality Assurance
- ICH: International Council for Harmonisation
7. Documents
- ATP Tracker – Annexure-1
- ATP Template – Annexure-2
- ATP Approval Sheet – Annexure-3
8. References
- ICH Q8(R2) – Pharmaceutical Development
- ICH Q14 – Analytical Procedure Development (Draft)
- ICH Q2(R1) – Validation of Analytical Procedures
- WHO TRS 996 – Good Practices for Pharmaceutical Quality
9. SOP Version
Version: 2.0
10. Approval Section
|
Prepared By |
Checked By |
Approved By |
Signature |
|
|
|
Date |
|
|
|
Name |
|
|
|
Designation |
|
|
|
Department |
|
|
|
11. Annexures
Annexure-1: ATP Tracker
ATP No. |
Product |
Date Initiated |
Status |
Version |
ATP/25/015 |
Amlodipine Tablets |
14/05/2025 |
Approved |
1.0 |
Annexure-2: ATP Template
Section |
Details |
Analyte |
Amlodipine |
Objective |
To quantify Amlodipine in tablets using RP-HPLC |
Accuracy |
98.0% – 102.0% |
Precision |
%RSD ≤ 2.0% |
Range |
80% – 120% of target concentration |
Specificity |
No interference from placebo or impurities |
Detection |
UV at 238 nm |
Annexure-3: ATP Approval Sheet
Role |
Name |
Signature |
Date |
Prepared By |
|
|
|
Reviewed By |
|
|
|
Approved By |
|
|
|
Revision History:
Revision Date |
Revision No. |
Details |
Reason |
Approved By |
04/05/2025 |
2.0 |
Incorporated ICH Q14 framework and annexure-based documentation |
Regulatory alignment |
|